MA21682A1 - Procede de preparation d'agents therapeutiques derives de la quainclidine. - Google Patents

Procede de preparation d'agents therapeutiques derives de la quainclidine.

Info

Publication number
MA21682A1
MA21682A1 MA21938A MA21938A MA21682A1 MA 21682 A1 MA21682 A1 MA 21682A1 MA 21938 A MA21938 A MA 21938A MA 21938 A MA21938 A MA 21938A MA 21682 A1 MA21682 A1 MA 21682A1
Authority
MA
Morocco
Prior art keywords
quainclidine
preparation
therapeutic agents
agents derived
derived
Prior art date
Application number
MA21938A
Other languages
English (en)
Inventor
Adams John
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA21682A1 publication Critical patent/MA21682A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA21938A 1988-11-23 1989-11-22 Procede de preparation d'agents therapeutiques derives de la quainclidine. MA21682A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1988/004205 WO1990005525A1 (fr) 1988-11-23 1988-11-23 Derives de quinuclidine en tant qu'antagonsites de substance p

Publications (1)

Publication Number Publication Date
MA21682A1 true MA21682A1 (fr) 1990-07-01

Family

ID=22209014

Family Applications (1)

Application Number Title Priority Date Filing Date
MA21938A MA21682A1 (fr) 1988-11-23 1989-11-22 Procede de preparation d'agents therapeutiques derives de la quainclidine.

Country Status (29)

Country Link
US (1) US5162339A (fr)
EP (1) EP0409931B1 (fr)
JP (1) JPH0647589B2 (fr)
KR (1) KR900701782A (fr)
CN (1) CN1026111C (fr)
AP (1) AP120A (fr)
AR (1) AR246522A1 (fr)
AT (1) ATE101608T1 (fr)
AU (1) AU617906B2 (fr)
CA (1) CA2003441C (fr)
DD (1) DD285605A5 (fr)
DE (1) DE68913194T2 (fr)
EG (1) EG19301A (fr)
ES (1) ES2062504T3 (fr)
FI (1) FI903656A0 (fr)
HU (1) HU900517D0 (fr)
IE (1) IE893730L (fr)
IL (1) IL92336A0 (fr)
MA (1) MA21682A1 (fr)
MX (1) MX18467A (fr)
MY (1) MY105061A (fr)
NZ (1) NZ231461A (fr)
OA (1) OA10023A (fr)
PH (1) PH26590A (fr)
PL (1) PL161864B1 (fr)
PT (1) PT92361B (fr)
WO (2) WO1990005525A1 (fr)
YU (1) YU47097B (fr)
ZA (1) ZA898901B (fr)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001124B (el) * 1989-11-20 1993-04-28 Pfizer Θεραπευτικοι παραγοντες κουινουκλιδινης.
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド ３―アミノ―２―アリールキヌクリジン
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
ATE121389T1 (de) * 1990-09-28 1995-05-15 Pfizer Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
US5216163A (en) * 1991-01-03 1993-06-01 Pfizer Inc Process for preparing azabicyclo[2.2.2]octan-3-imines
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
CA2100163A1 (fr) * 1991-01-10 1992-07-11 John A. Lowe, Iii Sels de n-alkylquinuclidinium
US5242930A (en) * 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
DE69200921T2 (de) * 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
AU647592B2 (en) * 1991-03-26 1994-03-24 Pfizer Inc. Stereoselective preparation of substituted piperidines
FR2676442B1 (fr) * 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5292726A (en) * 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
RU2092486C1 (ru) * 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (fr) * 1991-06-21 1993-03-21 Pfizer
US5288730A (en) * 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
EP0536817A1 (fr) * 1991-07-05 1993-04-14 MERCK SHARP & DOHME LTD. Composés azabicycliques comme antagonistes des tachykinines
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CA2112397A1 (fr) * 1991-08-20 1993-03-04 Raymond Baker Composes azacyclique, procedes pour les preparer et compositions pharmaceutiques les contenant
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0607164B1 (fr) * 1991-09-26 2002-05-02 Pfizer Inc. Heterocycles tricycliques fusionnes, contenant de l'azote, utilises comme antagonistes de recepteur de substance p
JP2553020B2 (ja) * 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
ES2111650T3 (es) * 1991-11-12 1998-03-16 Pfizer Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
AU675786B2 (en) * 1992-04-15 1997-02-20 Merck Sharp & Dohme Limited Azacyclic compounds
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
JP2683783B2 (ja) * 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
JP2909214B2 (ja) * 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
FR2695641B1 (fr) * 1992-09-11 1994-11-25 Rhone Poulenc Rorer Sa (Amino-3 phényl)-1 éthanesulfonate d'hydroquinine optiquement actif, sa préparation et son utilisation.
JP2656699B2 (ja) * 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
NZ254604A (en) * 1992-11-12 1997-06-24 Pfizer Quinuclidine derivative and pharmaceutical compositions thereof
ES2147759T3 (es) * 1992-12-10 2000-10-01 Pfizer Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
EP0687268B1 (fr) * 1993-03-04 1998-05-27 Pfizer Inc. Derives spiroazacycliques utilises comme antagonistes de la substance p
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
CA2167198C (fr) * 1993-07-15 1999-03-16 Kunio Satake Benzylaminoquinuclidines
US5854262A (en) * 1993-10-07 1998-12-29 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5922878A (en) * 1994-03-03 1999-07-13 Boehringer Ingelheim Gmbh Amino acid derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
PE45195A1 (es) * 1994-03-03 1996-01-17 Boehringer Ingelheim Kg Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2719476B1 (fr) * 1994-05-05 1997-05-23 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
FR2719474B1 (fr) 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
JP3042894B2 (ja) 1995-07-07 2000-05-22 ファイザー製薬株式会社 サブスタンスｐアンタゴニストとしての置換ベンゾラクタム化合物
US6288225B1 (en) 1996-05-09 2001-09-11 Pfizer Inc Substituted benzolactam compounds as substance P antagonists
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
EP0942728A1 (fr) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles de la sexualite
WO1998024444A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles du sevrage
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
WO1998024443A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles bipolaires
WO1998024446A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies
WO1998024447A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 en traitement de troubles cognitifs
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
WO2000010545A2 (fr) * 1998-08-25 2000-03-02 Novartis Ag Utilisations pharmaceutiques
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
CA2324116A1 (fr) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Antagonistes du recepteur nk-1 et eletriptan pour le traitement de la migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
MXPA03000275A (es) 2000-07-11 2004-12-13 Albany Molecular Res Inc Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
EP1411946A1 (fr) * 2001-07-20 2004-04-28 Pfizer Products Inc. Utilisation d'antagonistes du recepteur nk-1 pour modifier un comportement indesirable chez des chiens, des chats et des chevaux
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
CA2514656A1 (fr) * 2003-01-31 2004-08-12 Pfizer Products Inc. Antagonistes 5ht7 et agonistes inverses
WO2005043153A1 (fr) * 2003-10-27 2005-05-12 Meyer Donald W Detection de l'encephalopathie spongiforme transmissible chez les cervides, l'espece ovine et l'espece caprine
CA2547283C (fr) * 2003-11-26 2010-11-09 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
WO2009002495A1 (fr) 2007-06-27 2008-12-31 Merck & Co., Inc. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
CA2777043C (fr) 2009-10-14 2015-12-15 Schering Corporation Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
CA2882950A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composes inhibiteurs de erk
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (fr) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2019094312A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
CA3108388A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033285A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (fr) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine
EP4010314B1 (fr) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
EP4076460B1 (fr) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC Dérivés de 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine] en tant qu'inhibiteurs de prmt5 pour le traitement du cancer
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534053A (en) * 1967-05-24 1970-10-13 American Home Prod Quinuclidine derivatives
US3506673A (en) * 1968-03-29 1970-04-14 Aldrich Chem Co Inc 2-(4'halo)-benzhydryl-3-quinuclidinols
US3506672A (en) * 1968-03-29 1970-04-14 Aldrich Chem Co Inc 2-(4,4'-dihalo)-benzhydryl-3-quinuclidinols
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US3917612A (en) * 1971-07-27 1975-11-04 Hoffmann La Roche 1,1-Dichloro-3-(4-piperidinyl)propan-2-ols
BE789679A (fr) * 1971-10-05 1973-04-04 Leo Pharm Prod Ltd Nouveaux derives d'acide amino-5 isophtalique et leurs procedesde preparation
US3933906A (en) * 1972-10-13 1976-01-20 Ciba-Geigy Corporation 3,4-Bisamino-5-sulfamoylbenzoic acids
FR2529548A1 (fr) * 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
ES2051753T3 (es) * 1986-12-16 1994-07-01 Robins Co Inc A H N-(1-azabiciclo(2.2.2)octo-3-il) benzamidas y tiobenzamidas ansioliticas.
DE3881950T2 (de) * 1987-04-25 1993-09-30 Beecham Group Plc Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.

Also Published As

Publication number Publication date
PH26590A (en) 1992-08-19
DD285605A5 (de) 1990-12-19
HU900517D0 (en) 1991-05-28
YU222289A (en) 1991-04-30
CA2003441C (fr) 1998-04-07
NZ231461A (en) 1991-01-29
WO1990005729A1 (fr) 1990-05-31
PT92361B (pt) 1995-07-18
EP0409931B1 (fr) 1994-02-16
PL161864B1 (pl) 1993-08-31
DE68913194T2 (de) 1994-05-19
ES2062504T3 (es) 1994-12-16
EG19301A (en) 1994-10-30
FI903656A7 (fi) 1990-07-19
MX18467A (es) 1993-07-01
IL92336A0 (en) 1990-07-26
MY105061A (en) 1994-07-30
DE68913194D1 (en) 1994-03-24
US5162339A (en) 1992-11-10
YU47097B (sh) 1994-12-28
AU4661989A (en) 1990-06-12
WO1990005525A1 (fr) 1990-05-31
PT92361A (pt) 1990-05-31
IE893730L (en) 1990-05-23
CN1026111C (zh) 1994-10-05
AU617906B2 (en) 1991-12-05
OA10023A (en) 1996-10-14
JPH0647589B2 (ja) 1994-06-22
JPH03503768A (ja) 1991-08-22
AP8900152A0 (en) 1990-01-31
KR900701782A (ko) 1990-12-04
ATE101608T1 (de) 1994-03-15
AP120A (en) 1991-02-20
EP0409931A1 (fr) 1991-01-30
FI903656A0 (fi) 1990-07-19
CA2003441A1 (fr) 1990-05-23
ZA898901B (en) 1991-10-30
AR246522A1 (es) 1994-08-31
CN1043130A (zh) 1990-06-20

Similar Documents

Publication Publication Date Title
MA22481A1 (fr) Procede de preparation d'acides imidazolyl - alcenoiques .
MA22626A1 (fr) Procede de preparation d'acides imidazolyl-alcenoiques .
MA22668A1 (fr) Procede de preparation d'oxamides .
FI872379A7 (fi) Menetelmä farmakologisesti vaikuttavien 1,5-diaryyli-3-(w-substituoitu-alempi-alkyyli)-pyratsolien valmistamiseksi
MA23091A1 (fr) Procede de preparation d'agents antiparasitaires .
MA21645A1 (fr) Procede pour la preparation de nouveaux derives d'rtemisinine.
FI891338A0 (fi) Parannus menetelmään 2',3'-dideoksi-2',3'-didehydronukleosidien valmistamiseksi
MA21922A1 (fr) Procede de purification d'acides aminomethylene-phosphoniques .
FI903752A7 (fi) Menetelmä 1,2,3,4-tetrahydro-9-akridiiniamiinin johdannaisten valmistamiseksi
FR2627493B1 (fr) Procede de preparation de derives d'isoquinoleine
MA21122A1 (fr) Procede de preparation de derives d'acides aminocarboxyliques bicycliques .
ITMI913465A0 (it) Procedimento per la depurazione dell'1.1.1-trifluoro-2-fuoroetano
IT8820935A0 (it) Procedimento per la preparazione di 1,2,5,6,9,10 esabromociclododecano.
FI896075A7 (fi) Menetelmä 4,5,6,7-tetrahydrobentsimidatsolijohdosten valmistamiseksi
FR2708266B1 (fr) Procédé de préparation d'alcanesulfonamides.
FR2630735B1 (fr) Procede de preparations d'halogenophenols
FR2620702B1 (fr) Procede de preparation d'irones naturelles
FR2644161B1 (fr) Procede de preparation d'amides n-arylsubstitues
FI893121L (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
FR2630741B1 (fr) Procede de preparation d'acryloyloxyethoxymethyl-melamines
FR2610924B1 (fr) Procede de preparation d'hydroxybiphenyles
FR2605318B1 (fr) Procede de preparation d'azetidinones.
FI930237A7 (fi) Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi
IT8321080A0 (it) Procedimento per la preparazione dell'estere metilico di alfa-l-aspartil-l-fenil-alanina.
EP0643724A4 (fr) Procede d'elaboration de 3-carbonylandrostadiene 17-carboxamides.